annual CFI:
-$83.28M-$160.82M(-207.40%)Summary
- As of today (September 17, 2025), PCRX annual cash flow from investing activities is -$83.28 million, with the most recent change of -$160.82 million (-207.40%) on December 31, 2024.
- During the last 3 years, PCRX annual CFI has fallen by -$62.49 million (-300.56%).
- PCRX annual CFI is now -207.40% below its all-time high of $77.54 million, reached on December 31, 2023.
Performance
PCRX Cash from investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFI:
$62.16M+$87.79M(+342.55%)Summary
- As of today (September 17, 2025), PCRX quarterly cash flow from investing activities is $62.16 million, with the most recent change of +$87.79 million (+342.55%) on June 30, 2025.
- Over the past year, PCRX quarterly CFI has increased by +$77.38 million (+508.56%).
- PCRX quarterly CFI is now -34.19% below its all-time high of $94.46 million, reached on September 30, 2018.
Performance
PCRX quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFI:
-$16.00M+$77.38M(+82.87%)Summary
- As of today (September 17, 2025), PCRX TTM cash flow from investing activities is -$16.00 million, with the most recent change of +$77.38 million (+82.87%) on June 30, 2025.
- Over the past year, PCRX TTM CFI has increased by +$10.72 million (+40.12%).
- PCRX TTM CFI is now -110.49% below its all-time high of $152.44 million, reached on September 30, 2018.
Performance
PCRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
PCRX Cash from investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -207.4% | +508.6% | +40.1% |
| 3 y3 years | -300.6% | +224.4% | +89.8% |
| 5 y5 years | +35.2% | +72.1% | +9.2% |
PCRX Cash from investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -207.4% | +63.0% | -6.1% | +219.2% | -119.9% | +92.9% |
| 5 y | 5-year | -207.4% | +70.0% | -7.1% | +129.9% | -119.9% | +95.3% |
| alltime | all time | -207.4% | +70.0% | -34.2% | +129.9% | -110.5% | +95.3% |
PCRX Cash from investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $62.16M(-342.5%) | -$16.00M(-82.9%) |
| Mar 2025 | - | -$25.63M(+6864.4%) | -$93.38M(+12.1%) |
| Dec 2024 | -$83.28M(-207.4%) | -$368.00K(-99.3%) | -$83.28M(+11.7%) |
| Sep 2024 | - | -$52.16M(+242.8%) | -$74.53M(+179.0%) |
| Jun 2024 | - | -$15.21M(-2.0%) | -$26.71M(+540.3%) |
| Mar 2024 | - | -$15.53M(-285.5%) | -$4.17M(-105.4%) |
| Dec 2023 | $77.54M(-134.4%) | $8.37M(-292.9%) | $77.54M(-3.5%) |
| Sep 2023 | - | -$4.34M(-159.3%) | $80.36M(+116.1%) |
| Jun 2023 | - | $7.33M(-88.9%) | $37.18M(-24.1%) |
| Mar 2023 | - | $66.18M(+491.5%) | $49.02M(-121.8%) |
| Dec 2022 | -$225.19M(+983.1%) | $11.19M(-123.5%) | -$225.19M(+32.9%) |
| Sep 2022 | - | -$47.52M(-348.0%) | -$169.46M(+7.9%) |
| Jun 2022 | - | $19.16M(-109.2%) | -$157.02M(-9.3%) |
| Mar 2022 | - | -$208.02M(-410.9%) | -$173.15M(+732.8%) |
| Dec 2021 | -$20.79M(-92.5%) | $66.92M(-290.8%) | -$20.79M(-87.8%) |
| Sep 2021 | - | -$35.08M(-1256.5%) | -$170.03M(-49.7%) |
| Jun 2021 | - | $3.03M(-105.4%) | -$337.80M(+10.9%) |
| Mar 2021 | - | -$55.66M(-32.4%) | -$304.70M(+9.8%) |
| Dec 2020 | -$277.61M(+116.1%) | -$82.32M(-59.4%) | -$277.61M(+22.8%) |
| Sep 2020 | - | -$202.85M(-661.5%) | -$226.09M(+1183.6%) |
| Jun 2020 | - | $36.12M(-226.5%) | -$17.61M(-92.5%) |
| Mar 2020 | - | -$28.57M(-7.2%) | -$235.53M(+83.3%) |
| Dec 2019 | -$128.49M(-724.5%) | -$30.80M(-647.5%) | -$128.49M(-41.8%) |
| Sep 2019 | - | $5.63M(-103.1%) | -$220.86M(+67.3%) |
| Jun 2019 | - | -$181.80M(-331.6%) | -$132.02M(-220.7%) |
| Mar 2019 | - | $78.48M(-163.7%) | $109.35M(+431.4%) |
| Dec 2018 | $20.58M(-109.2%) | -$123.16M(-230.4%) | $20.58M(-86.5%) |
| Sep 2018 | - | $94.46M(+58.6%) | $152.44M(+399.8%) |
| Jun 2018 | - | $59.57M(-678.8%) | $30.50M(-133.8%) |
| Mar 2018 | - | -$10.29M(-218.3%) | -$90.22M(-59.7%) |
| Dec 2017 | -$223.76M | $8.70M(-131.7%) | -$223.76M(-6.5%) |
| Sep 2017 | - | -$27.48M(-55.1%) | -$239.38M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$61.15M(-57.5%) | -$225.22M(+22.6%) |
| Mar 2017 | - | -$143.84M(+1979.5%) | -$183.72M(+197.5%) |
| Dec 2016 | -$61.75M(+220.7%) | -$6.92M(-48.1%) | -$61.75M(+29.8%) |
| Sep 2016 | - | -$13.32M(-32.2%) | -$47.58M(+15.8%) |
| Jun 2016 | - | -$19.64M(-10.2%) | -$41.10M(+0.4%) |
| Mar 2016 | - | -$21.88M(-401.5%) | -$40.94M(+102.4%) |
| Dec 2015 | -$19.26M(-83.9%) | $7.25M(-206.1%) | -$20.23M(-13.8%) |
| Sep 2015 | - | -$6.84M(-64.9%) | -$23.47M(-80.2%) |
| Jun 2015 | - | -$19.48M(+1575.2%) | -$118.43M(-8.6%) |
| Mar 2015 | - | -$1.16M(-129.0%) | -$129.52M(+8.5%) |
| Dec 2014 | -$119.34M(+174.0%) | $4.02M(-103.9%) | -$119.34M(+9.7%) |
| Sep 2014 | - | -$101.80M(+233.0%) | -$108.76M(+3155.2%) |
| Jun 2014 | - | -$30.57M(-439.0%) | -$3.34M(-115.4%) |
| Mar 2014 | - | $9.02M(-38.2%) | $21.71M(-149.8%) |
| Dec 2013 | -$43.56M(+47.6%) | $14.60M(+303.8%) | -$43.56M(+21.7%) |
| Sep 2013 | - | $3.62M(-165.5%) | -$35.80M(-13.2%) |
| Jun 2013 | - | -$5.52M(-90.2%) | -$41.22M(-50.5%) |
| Mar 2013 | - | -$56.25M(-351.6%) | -$83.24M(+182.0%) |
| Dec 2012 | -$29.52M(-18.3%) | $22.36M(-1336.0%) | -$29.52M(-53.6%) |
| Sep 2012 | - | -$1.81M(-96.2%) | -$63.65M(-1.2%) |
| Jun 2012 | - | -$47.54M(+1779.1%) | -$64.41M(+70.3%) |
| Mar 2012 | - | -$2.53M(-78.5%) | -$37.82M(+4.7%) |
| Dec 2011 | -$36.12M(+433.7%) | -$11.77M(+358.8%) | -$36.12M(+32.3%) |
| Sep 2011 | - | -$2.56M(-87.8%) | -$27.30M(+2.5%) |
| Jun 2011 | - | -$20.96M(+2419.0%) | -$26.64M(+270.8%) |
| Mar 2011 | - | -$832.00K(-71.8%) | -$7.18M(+6.1%) |
| Dec 2010 | -$6.77M(+22.9%) | -$2.95M(+55.3%) | -$6.77M(+77.1%) |
| Sep 2010 | - | -$1.90M(+26.0%) | -$3.82M(+98.7%) |
| Jun 2010 | - | -$1.51M(+261.2%) | -$1.92M(+361.2%) |
| Mar 2010 | - | -$417.00K | -$417.00K |
| Dec 2009 | -$5.51M(-5.6%) | - | - |
| Dec 2008 | -$5.84M(-76.0%) | - | - |
| Dec 2007 | -$24.38M | - | - |
FAQ
- What is Pacira BioSciences, Inc. annual cash flow from investing activities?
- What is the all time high annual CFI for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. annual CFI year-on-year change?
- What is Pacira BioSciences, Inc. quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. quarterly CFI year-on-year change?
- What is Pacira BioSciences, Inc. TTM cash flow from investing activities?
- What is the all time high TTM CFI for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. TTM CFI year-on-year change?
What is Pacira BioSciences, Inc. annual cash flow from investing activities?
The current annual CFI of PCRX is -$83.28M
What is the all time high annual CFI for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high annual cash flow from investing activities is $77.54M
What is Pacira BioSciences, Inc. annual CFI year-on-year change?
Over the past year, PCRX annual cash flow from investing activities has changed by -$160.82M (-207.40%)
What is Pacira BioSciences, Inc. quarterly cash flow from investing activities?
The current quarterly CFI of PCRX is $62.16M
What is the all time high quarterly CFI for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high quarterly cash flow from investing activities is $94.46M
What is Pacira BioSciences, Inc. quarterly CFI year-on-year change?
Over the past year, PCRX quarterly cash flow from investing activities has changed by +$77.38M (+508.56%)
What is Pacira BioSciences, Inc. TTM cash flow from investing activities?
The current TTM CFI of PCRX is -$16.00M
What is the all time high TTM CFI for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high TTM cash flow from investing activities is $152.44M
What is Pacira BioSciences, Inc. TTM CFI year-on-year change?
Over the past year, PCRX TTM cash flow from investing activities has changed by +$10.72M (+40.12%)